Voyageur Pharmaceuticals Ltd. (TSX-V: VM)(OTC Pink: VYYRF) announced on March 4, 2026, that independent laboratory testing confirmed its barium sulfate active pharmaceutical ingredient (API) from the Frances Creek barite property in British Columbia achieves pharmaceutical-grade purity, with results exceeding USP monograph requirements. The testing, part of the Alberta Innovates AICE-Market Access Program, showed an average purity of 98.8% BaSO4 across multiple samples, surpassing the 97.5% USP requirement. All samples passed complete USP monograph tests, including heavy metal limits significantly below specifications, and achieved successful micronization to 1-micron particle sizes. The company now moves to stage two of the program, which involves manufacturing barium contrast agents for a Health Canada-approved human clinical trial targeting completion in the fourth quarter of 2026.
Brent Willis, CEO of Voyageur, stated that these results represent a major de-risking milestone, proving that the natural barite resource delivers high chemical purity and full USP compliance. The upcoming clinical trial will compare Voyageur's contrasts with current standard-of-care options for gastrointestinal CT and fluoroscopic imaging. Successful outcomes are expected to validate clinical performance, strengthen regulatory positioning with Health Canada and the FDA, and accelerate market adoption. The company plans to begin the FDA process in the first quarter of 2026 and expects to complete a prefeasibility study for the Frances Creek project by the fourth quarter of 2026.
Voyageur is building a vertically integrated supply chain from quarry to finished contrast media, aiming to reduce reliance on imported or synthetic materials. The company also announced grants of stock options and deferred share units (DSUs) to directors and officers, as well as a proposed issuance of securities for debt to an arm's length provider. The DSUs and options are subject to TSX Venture Exchange approval. More details are available on the company's website at https://voyageurpharmaceuticals.ca.
